Advertisement

Topics

Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of Yupelri in COPD

12:06 EDT 19 Sep 2018 | Speciality Pharma Journal

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2018 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ :TBPH ) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ :MYL ) (“Mylan”) today announced that positive new data from the companies’ Phase 3 clinical program for YUPELRI™ (revefenacin) inhalation solution were featured in an oral presentation at the European Respiratory Society …

Original Article: Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of Yupelri in COPD

NEXT ARTICLE

More From BioPortfolio on "Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of Yupelri in COPD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...